Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,182.00
Bid: 12,182.00
Ask: 12,186.00
Change: 86.00 (0.71%)
Spread: 4.00 (0.033%)
Open: 12,150.00
High: 12,266.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Japan approves more COVID-19 vaccines and expands state of emergency

Fri, 21st May 2021 04:06

(Updates with official announcement on Okinawa)

By Chang-Ran Kim

TOKYO, May 21 (Reuters) - Japan expanded a state of
emergency to cover the southern island of Okinawa on Friday,
just as it approved two more coronavirus vaccines to speed up
its lagging inoculation campaign.

The newly approved vaccines, from Moderna Inc and
AstraZeneca PLC, will join the one co-developed by
Pfizer Inc and BioNTech SE in a vaccination
drive that began in mid-February.

But AstraZeneca's vaccine would not be used for the time
being, the company said. Earlier media reports said the
government would hold off on their use due to concerns over
blood clots and bleeding in some people.

"We are aware that our vaccine is not going to be used right
away," a spokeswoman at AstraZeneca said. Japan has arranged to
buy 120 million doses of the British-Swedish drugmaker's
vaccine.

Japan has so far vaccinated just 4.1% of its population,
according to Reuters' global tracker https://tmsnrt.rs/3vbj5CE,
the slowest rate among the world's larger, rich countries.

In contrast to some other Group of Seven (G7) countries that
are beginning to end pandemic-busting lockdown measures, much of
Japan remains under emergency curbs amid a fourth wave of
infections.

On Friday, the government added Okinawa to its list of nine
prefectures under the strictest emergency measures. They include
Tokyo, where the Olympic Games are due to start in about two
months.

JAPAN INC, PUBLIC FEARS OVER OLYMPICS

Fears that the Olympics would turn into a super-spreader
event have persisted, keeping the majority of the public opposed
to holding the Games this year. A Reuters corporate survey https://jp.reuters.com/article/us-olympics-2020-japan-companies-poll/fretting-about-covid-most-japan-firms-say-olympics-should-be-cancelled-or-postponed-reuters-poll-idUSKCN2D12SZ
published on Friday showed nearly 70% of Japanese firms also
want the Games either cancelled or postponed.

The state of emergency for Okinawa would run for about a
month from Sunday through June 20, Prime Minister Yoshihide Suga
said, beyond the May 31 end of the other nine.

The move marks the third consecutive week that Japan has
expanded the state of emergency.

Japan has so far recorded about 695,000 novel coronavirus
infections and 12,000 COVID-19 deaths - much fewer than many
countries - but its medical system is increasingly strained by a
spike in more infectious variants of the virus.

With the Olympics starting on July 23, Tokyo is under
particular pressure to bring infections and strain on the
medical system down from the most dire "Stage Four" level and
emerge from a state of emergency as scheduled this month.

After a 30-minute meeting with Suga on Friday, Tokyo
Governor Yuriko Koike said she requested a sufficient supply of
vaccines for the capital as it begins mass-vaccinations next
week, and said the two shared their commitment to working
towards a "safe and secure" Olympics this summer.
(Reporting by Chang-Ran Kim; Additional reporting by Rocky
Swift; Editing by Simon Cameron-Moore and Christopher Cushing)

More News
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.